ArticleVirus genes2026
The relationship between mutations in reverse transcriptase region of hepatitis B virus and progression of liver disease.
Article in Virus genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The specific objective of this study was to investigate mutations of Hepatitis B virus (HBV) reverse transcriptase (RT) region in Chinese HBV-infected patients at different stages and their association with the progression of liver disease. HBV RT regions in serum samples were amplified and sequenced from 384 patients with chronic HBV infection, including 100 asymptomatic carriers (ASC), 101 chronic hepatitis B, 96 liver cirrhosis, and 87 hepatocellular carcinoma (HCC). Further analysis of genotyping and AA substitution within RT was performed by the online HBV genotyping tool and MEGA7.0 software. A logistic regression model was used to explore the relationship between RT mutations and advanced liver disease (ALD). The mutation rate gradually increased from ASC to HCC (P for trend < 0.05). Logistic regression analysis showed that one RT site mutation, rtS106A/C, was significantly associated with the ALD. Multivariate regression analysis confirmed that two RT mutations, rtH55R/Q/K and rtS137T/Q/E, were independent risk factors for HBV-related HCC. The current study reveals that mutations within the RT region might be associated with the progression of HBV-related liver diseases and might serve as predictive biomarkers for patients with HBV infection at high risk of developing HCC.
Indexed as
Identifiers
42518075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.